Advertisement
Screener

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Increase (Decrease) in Accounts Payable, Trade

2.8 / 5 stars · 68/120 Roast Me

BLACK DIAMOND THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Increase (Decrease) in Accounts Payable, Trade of $825.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-05

  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$1.56M.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $2.39M.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$396.00K, a 119.45% decline year-over-year.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $204.00K, a 83.11% decline year-over-year.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was -$3.43M, a 303.68% decline from fiscal 2024.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was $1.68M, a 181.91% increase from fiscal 2023.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $597.00K.
  • BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was -$2.23M, a 242.13% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable, Trade 3 monthIncrease (Decrease) in Accounts Payable, Trade 6 monthIncrease (Decrease) in Accounts Payable, Trade 9 monthIncrease (Decrease) in Accounts Payable, Trade 12 month
2026-06-30-$1.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$825.00K
10-Q · filed 2026-08-05
$429.00K
derived: sum of 3 quarters · filed 2026-08-05
$633.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$2.39M
10-Q · filed 2026-05-07
$1.99M
derived: sum of 2 quarters · filed 2026-05-07
$2.20M
derived: sum of 3 quarters · filed 2026-05-07
$341.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$396.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$192.00K
derived: sum of 2 quarters · filed 2026-03-16
-$2.05M
derived: sum of 3 quarters · filed 2026-08-05
-$3.43M
10-K · filed 2026-03-16
2025-09-30$204.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$1.65M
derived: sum of 2 quarters · filed 2026-08-05
-$3.03M
10-Q · filed 2025-11-06
-$996.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$1.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$3.24M
10-Q · filed 2026-08-05
-$1.20M
derived: sum of 3 quarters · filed 2026-08-05
$8.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$1.38M
10-Q · filed 2026-05-07
$657.00K
derived: sum of 2 quarters · filed 2026-05-07
$1.86M
derived: sum of 3 quarters · filed 2026-05-07
$1.43M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$2.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$3.24M
derived: sum of 2 quarters · filed 2026-03-16
$2.81M
derived: sum of 3 quarters · filed 2026-03-16
$1.68M
10-K · filed 2026-03-16
2024-09-30$1.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$775.00K
derived: sum of 2 quarters · filed 2025-11-06
-$353.00K
10-Q · filed 2025-11-06
$1.28M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$433.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$1.56M
10-Q · filed 2025-08-07
$69.00K
derived: sum of 3 quarters · filed 2025-08-07
-$1.79M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$1.13M
10-Q · filed 2025-05-12
$502.00K
derived: sum of 2 quarters · filed 2025-05-12
-$1.36M
derived: sum of 3 quarters · filed 2025-05-12
-$1.70M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$1.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
-$229.00K
derived: sum of 2 quarters · filed 2025-03-06
-$572.00K
derived: sum of 3 quarters · filed 2025-03-06
$597.00K
10-K · filed 2025-03-06
2023-09-30-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
-$2.20M
derived: sum of 2 quarters · filed 2024-11-05
-$1.03M
10-Q · filed 2024-11-05
-$4.92M
derived: sum of 4 quarters · filed 2024-11-05
2023-06-30-$343.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$826.00K
10-Q · filed 2024-08-06
-$3.06M
derived: sum of 3 quarters · filed 2024-08-06
$481.00K
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$1.17M
10-Q · filed 2024-05-09
-$2.71M
derived: sum of 2 quarters · filed 2024-05-09
$824.00K
derived: sum of 3 quarters · filed 2024-05-09
$1.16M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$3.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$345.00K
derived: sum of 2 quarters · filed 2024-03-12
-$6.00K
derived: sum of 3 quarters · filed 2024-03-12
-$2.23M
10-K · filed 2024-03-12
2022-09-30$3.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$3.88M
derived: sum of 2 quarters · filed 2023-11-06
$1.65M
10-Q · filed 2023-11-06
$959.00K
derived: sum of 4 quarters · filed 2023-11-06
2022-06-30$339.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$1.89M
10-Q · filed 2023-08-11
-$2.58M
derived: sum of 3 quarters · filed 2023-08-11
-$1.95M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$2.22M
10-Q · filed 2023-05-09
-$2.92M
derived: sum of 2 quarters · filed 2023-05-09
-$2.29M
derived: sum of 3 quarters · filed 2023-05-09
-$2.65M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$694.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
-$66.00K
derived: sum of 2 quarters · filed 2023-03-09
-$422.00K
derived: sum of 3 quarters · filed 2023-03-09
$1.57M
10-K · filed 2023-03-09
2021-09-30$628.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$272.00K
derived: sum of 2 quarters · filed 2022-11-08
$2.26M
10-Q · filed 2022-11-08
$1.80M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$356.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$1.64M
10-Q · filed 2022-08-09
$1.18M
derived: sum of 3 quarters · filed 2022-08-09
$4.06M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$1.99M
10-Q · filed 2022-05-11
$1.53M
derived: sum of 2 quarters · filed 2022-05-11
$4.42M
derived: sum of 3 quarters · filed 2022-05-11
$666.00K
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31-$459.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$2.43M
derived: sum of 2 quarters · filed 2022-03-17
-$1.32M
derived: sum of 3 quarters · filed 2022-03-17
$1.07M
10-K · filed 2022-03-17
2020-09-30$2.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$866.00K
derived: sum of 2 quarters · filed 2021-11-08
$1.53M
10-Q · filed 2021-11-08
$2.49M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30-$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$1.36M
10-Q · filed 2021-08-12
-$401.00K
derived: sum of 3 quarters · filed 2021-08-12
-$175.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$2.39M
10-Q · filed 2021-05-07
$3.35M
derived: sum of 2 quarters · filed 2021-05-07
$3.58M
derived: sum of 3 quarters · filed 2021-05-07
$3.90M
derived: sum of 4 quarters · filed 2021-05-07
2019-12-31$958.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$1.18M
derived: sum of 2 quarters · filed 2021-03-25
$1.51M
derived: sum of 3 quarters · filed 2021-03-25
$1.45M
10-K · filed 2021-03-25
2019-09-30$226.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$550.00K
derived: sum of 2 quarters · filed 2020-11-10
$496.00K
10-Q · filed 2020-11-10
2019-06-30$324.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
$270.00K
10-Q · filed 2020-08-11
2019-03-31-$54.00K
10-Q · filed 2020-05-12
2018-12-31$264.00K
10-K · filed 2020-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Vaxart, Inc. (VXRT)United States$0.080B3.84